Hydrodynamic Plasmid Delivery

The rapid administration of a large fluid volume creates a sudden hydrodynamic pressure increase in the circulation. This pressure expands blood vessels and temporarily raises cell membrane permeability, creating a short window during which plasmid DNA can enter cells. The physical nature of this process allows gene transfer without requiring a viral vector.

Tail-vein administration produces prominent delivery to the liver, where hepatocytes can take up the introduced plasmids during the pressure-induced increase in permeability. This targeting is particularly useful when researchers need transient protein production from liver cells in living mice, including studies of immune mediators, antigens, or pathogen-associated proteins.

The defining delivery conditions are the size of the injected fluid volume and the speed of administration. A large volume delivered rapidly generates the pressure change needed for vessel expansion and temporary membrane permeability. Altering these physical conditions can therefore affect whether plasmids reach cells efficiently and whether transient gene expression is achieved.

Hydrodynamic plasmid delivery transfers DNA through a physical pressure-based process rather than through a viral vector. Its principal outcome is transient gene expression, which makes the approach useful when researchers need rapid, flexible production of a selected protein without establishing a viral delivery system. This distinction supports short-term experimental testing of gene function.

A typical experiment selects a plasmid encoding the molecule of interest, introduces it in a large fluid volume, and administers that volume rapidly, often through the tail vein in mice. The resulting pressure change promotes cellular uptake, after which investigators examine the transient expression of the encoded product in the relevant tissue or experimental model.

Researchers can use the method when they need in vivo production of cytokines, antigens, antibodies, or pathogen-associated proteins to examine immune responses. It also supports rapid tests of gene function and disease mechanisms. Because expression is transient and the approach is flexible, investigators can evaluate experimental immunotherapies without relying on viral vectors.

By producing pathogen-associated proteins or immune-active molecules inside a living model, the approach provides a way to examine how host responses develop in relation to specific gene products. In immunology and infection research, these experiments can help investigate disease mechanisms, characterize immune responses, and assess how candidate interventions influence those processes.